Affiliation: Aristotle University of Thessaloniki
Fountzilas G, Karkavelas G, Kalogera Fountzila A, Karina M, Ignatiadis M, Koukoulis G, et al
. Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res. 2006;26:4675-86 pubmed
..The combination of TMZ and irinotecan, as administered in this study, was accompanied by high rates of toxicity, especially myelotoxicity and infection. Further development of this regimen in the treatment of HGAT is not recommended. ..
Fountzilas G, Bobos M, Kalogera Fountzila A, Xiros N, Murray S, Linardou H, et al
. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest. 2008;26:784-93 pubmed publisher
..The 6-month progression-free survival (PFS) was 30%. Median PFS was 4.1 months and median survival 7.3 months with a 1 year survival rate of 27%. The above combination demonstrated promising activity in advanced pancreatic cancer. ..
Fountzilas G, Pectasides D, Kalogera Fountzila A, Skarlos D, Kalofonos H, Papadimitriou C, et al
. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat. 2005;92:1-9 pubmed
..7 and 42.7%, respectively), with the majority (72.1%) negative for cytoplasmic p27(kipl). The observed efficacy data in this study were similar to those reported for the combination of paclitaxel and carboplatin alone. ..
Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al
. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005;16:1762-71 pubmed
..However, our study has shown clearly that high-dose paclitaxel can be safely incorporated to dose-dense sequential chemotherapy. ..
Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos H, Briasoulis E, et al
. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2008;19:853-60 pubmed
..Both regimens as used in the present study are well tolerated and safe. The rates of severe taxane-related toxic effects and thrombocytopenia, although low overall, are significantly increased with the dose-dense sequential regimen. ..